ReviewHuman vaccines & immunotherapeutics2016
Fluzone® intra-dermal (Intanza®/Istivac® Intra-dermal): An updated overview.
Review in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Immunogenicity and Safety of Reduced-Dose Intradermal vs Intramuscular Influenza Vaccines: A Systematic Review and Meta-analysis.JAMA network open · 2021Pooled it
- Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence.Human vaccines & immunotherapeutics · 2019Pooled it
- Microneedle Technologies for Drug Delivery: Innovations, Applications, and Commercial Challenges.Micromachines · 2026Review
- Assessing the integrity and mechanical properties of commercial microneedles: innovation or fad?Drug delivery and translational research · 2025Article
- Engineering microneedles for biosensing and drug delivery.Bioactive materials · 2025Review
- An mRNA Vaccine for Herpes Zoster and Its Efficacy Evaluation in Naïve/Primed Murine Models.Vaccines · 2025Article
- A systematic review of microneedles technology in drug delivery through a bibliometric and patent overview.Heliyon · 2024Article
- Advanced Formulation Approaches for Proteins.Handbook of experimental pharmacology · 2024Review
- Review
- Microneedle-Based Vaccine Delivery: Review of an Emerging Technology.AAPS PharmSciTech · 2022Review
- An exploratory study to assess patterns of influenza- and pneumonia-related mortality among the Italian elderly.Human vaccines & immunotherapeutics · 2021Article
- COVID-19 vaccine platforms: Delivering on a promise?Human vaccines & immunotherapeutics · 2021Review
- Translation of Polymeric Microneedles for Treatment of Human Diseases: Recent Trends, Progress, and Challenges.Pharmaceutics · 2021Review
- Trends of microneedle technology in the scientific literature, patents, clinical trials and internet activity.Biomaterials · 2021Review
- Intradermal Delivery of Dendritic Cell-Targeting Chimeric mAbs Genetically Fused to Type 2 Dengue Virus Nonstructural Protein 1.Vaccines · 2020Article
- Review
- Review
- Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery.Scientific reports · 2019Article
- Immunogenicity, safety and tolerability of intradermal influenza vaccines.Human vaccines & immunotherapeutics · 2018Review
- Influenza vaccination in healthcare workers: A comprehensive critical appraisal of the literature.Human vaccines & immunotherapeutics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza is a highly contagious respiratory acute viral disease which imposes a very heavy burden both in terms of epidemiology and costs, in the developed countries as well as in the developing ones. It represents a serious public health concern and vaccination constitutes an important tool to reduce or at least mitigate its burden. Despite the existence of a broad armamentarium against influenza and despite all the efforts and recommendations of international organisms to broaden immunization, influenza vaccination coverage is still far from being optimal. This, taken together with logistic and technical difficulties that can result into vaccine shortage, makes intra-dermal (ID) vaccines, such as Fluzone® ID and Intanza®, particularly attractive. ID vaccines are comparable and, in some cases, superior to intra-muscular/sub-cutaneous vaccines in terms of immunogenicity, safety, reactogenicity, tolerability and cross-protection profiles, as well as in terms of patient preference, acceptance and vaccine selection. Further advances, such as Fluzone® ID with alternative B strains and Quadrivalent Fluzone® ID or the possibility of self-administering the vaccines, make influenza ID vaccines even more valuable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.